Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 101 results for "centrum broking"

MM margins quite healthy; expect better vols ahead: Expert

A Ajay Shethiya, VP- Auto & Auto Ancillary, Centrum Broking says EBITDA margin at 14.3 percent is quite healthy as compared to the earlier quarters on a like-to-like basis and therefore, he is positive in terms of the overall results. Echoing his ... Moneycontrol.com, 3 weeks ago

Broker's call - Dr Reddy's Labs: Buy

Centrum Broking Dr Reddy's Labs (Buy) CMP: ₹2,807.40 Target: ₹3,940 We maintain Buy rating on Dr Reddy's Labs with a revised target price of ₹3,940 (earlier ₹3,790) based on 23x June 2016E EPS of ₹171.2. Dr Reddy's results for Q1FY15 ...
 Hindu Business Line1 month ago DR REDDY LABORATORIES : sees price cuts in injectables in US  4 Traders3 weeks ago Dr Reddy's sees big price cuts in injectables in US  DNA India4 weeks ago
Sify

Experts bullish on Lupin after stellar Q1 performance

A Speaking to CNBC-TV18 post the result, Ranjit Kapadia of Centrum Broking expects Lupin to report a good performance on domestic front as well just like its peers Ranbaxy and Pfizer. He is highly bullish on the stocks backed by its strong Q1 ...
 Moneycontrol.com1 month ago Lupin: Earnings upgrades likely after stellar Q1  Smart Investor1 month ago

Sell Ranbaxy; Sun Pharma may test Rs 780: Ranjit Kapadia

Ranjit Kapadia of Centrum Broking is of the view that Sun Pharmaceutical Industries may test Rs 780.
 Money Control2 months ago Sun Pharma buys US drug maker  Smart Investor1 month ago Sun Pharma buys US-based injectable firm Pharmalucence  DNA India1 month ago Sun Pharma buys US injectables company  Hindu Business Line1 month ago
[x]  
Business Standard India

Share of MNC pharma brands to grow in FY15: Report

Centrum report says 6% price increase in controlled drugs, volume growth will boost numbers BS Reporter | Ahmedabad August 9, 2014 Last Updated at 17:08 IST Multinational pharma firms' share in the domestic pharma market is expected to go up to 20 ...
 Business Standard India3 weeks ago Pharma companies shrug off price control, grow domestic business  DNA India1 week ago Upward revision of drug prices help MNC pharma brands to grow  Business Standard India2 weeks ago

Diovan generic may fetch Ranbaxy $150 mn revenue: Centrum

There are host of players which are already there with Diovan HCT, seven players are already there in the market with a combination, so upside for Ranbaxy will be limited, says Ranjit Kapadia of Centrum Broking
 Money Control2 months ago

Sensex inches towards 27000; HDFC twins, pharma lead

12:20pm Auto sales to see strong growth? The festive season that started with Ganesh Chaturthi will augur well for the slacking automotive sector, believe industry experts Ajay Shethiya, Auto Analyst at Centrum Broking and Sundeep Kumar Bafna, MD ...
 Moneycontrol.com3 minutes ago
DNA India

IPCA Laboratories : Pharma cos may be hit by new price controls

Mumbai : The National Pharmaceutical Pricing Authority (NPPA) has fixed prices of ten combination drugs under Drugs Prices Control Order (DPCO), 2013. This is a part of a recent move taken by the NPPA to fix or revise prices in respect of 56 ...
 4 Traders2 days ago Fresh drug price control rule may hit Indian pharmaceutical companies  DNA India4 days ago NPPA moves to bring cancer drugs under price control regime  4 Traders1 month ago National Pharmaceutical Pricing Authority moves to bring cancer drugs under price control  DNA India1 month ago
Reuters

Markets This Month

By Ankush Arora and Sankalp Phartiyal The BSE Sensex jumped 2.9 percent in August, the seventh consecutive monthly gain for the benchmark index in 2014. The broader Nifty closed 3 percent higher, its fourth straight month of gains. The Indian ...
 Reuters3 days ago

RANBAXY LABORATORIES : may face another hefty fine in the US of Rs 240 crore

NEW DELHI : Ranbaxy Laboratories may have to pay another hefty fine in the United States of close to Rs 240 crore , this time imposed by the State of Texas , people familiar with the matter told ET. The company has been in negotiation with the US ...
 4 Traders4 days ago Ranbaxy Laboratories may face another hefty fine in the US of Rs 240 crore  Economic Times1 week ago Ranbaxy overcharged Texas for drugs under its public-funded Medicaid programme: US Report  Economic Times1 week ago US slaps Rs 240-crore fine on Ranbaxy Laboratories over for fraud in its Medicaid programme  Economic Times1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - centrum broking
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less